Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Cash & Current Investments (2020 - 2026)

RxSight filings provide 6 years of Cash & Current Investments readings, the most recent being $228.1 million for Q4 2025.

  • On a quarterly basis, Cash & Current Investments fell 50.16% to $228.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $228.1 million, a 50.16% decrease, with the full-year FY2025 number at $228.1 million, down 50.16% from a year prior.
  • Cash & Current Investments hit $228.1 million in Q4 2025 for RxSight, down from $425.4 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $457.7 million in Q4 2024 to a low of $80.7 million in Q2 2021.
  • Median Cash & Current Investments over the past 5 years was $233.3 million (2024), compared with a mean of $247.8 million.
  • Biggest five-year swings in Cash & Current Investments: skyrocketed 322.37% in 2021 and later tumbled 63.68% in 2022.
  • RxSight's Cash & Current Investments stood at $291.3 million in 2021, then tumbled by 63.68% to $105.8 million in 2022, then surged by 131.27% to $244.7 million in 2023, then soared by 87.06% to $457.7 million in 2024, then plummeted by 50.16% to $228.1 million in 2025.
  • The last three reported values for Cash & Current Investments were $228.1 million (Q4 2025), $425.4 million (Q3 2025), and $410.6 million (Q2 2025) per Business Quant data.